Khaled M Musallam

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9065382/publications.pdf

Version: 2024-02-01

185	7,593	57758	60623
papers	citations	44 h-index	81 g-index

186	186	186	6701
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Morbidity-free survival and hemoglobin level in non-transfusion-dependent Î²-thalassemia: a 10-year cohort study. Annals of Hematology, 2022, 101, 203-204.	1.8	21
2	Thalassemia and autoimmune diseases: Absence of evidence or evidence of absence?. Blood Reviews, 2022, 52, 100874.	5.7	6
3	Primary HBB gene mutation severity and longâ€term outcomes in a global cohort of Î²â€thalassaemia. British Journal of Haematology, 2022, 196, 414-423.	2.5	8
4	Mortality in Î²-thalassemia patients with confirmed pulmonary arterial hypertension on right heart catheterization. Blood, 2022, 139, 2080-2083.	1.4	10
5	Random Forest Clustering Identifies Three Subgroups of Î²-Thalassemia with Distinct Clinical Severity. Thalassemia Reports, 2022, 12, 14-23.	0.5	3
6	Risk of mortality from anemia and iron overload in nontransfusionâ€dependent Î²â€thalassemia. American Journal of Hematology, 2022, 97, .	4.1	19
7	Management of nonâ€transfusionâ€dependent Î²â€thalassemia (<scp>NTDT</scp>): The next 5â€‰years. American Journal of Hematology, 2021, 96, E57-E59.	4.1	11
8	Revisiting the nonâ€transfusionâ€dependent (NTDT) vs. transfusionâ€dependent (TDT) thalassemia classification 10 years later. American Journal of Hematology, 2021, 96, E54-E56.	4.1	28
9	Î²-Thalassemias. New England Journal of Medicine, 2021, 384, 727-743.	27.0	183
10	Variations in hemoglobin level and morbidity burden in non-transfusion-dependent Î²-thalassemia. Annals of Hematology, 2021, 100, 1903-1905.	1.8	20
11	Survival and causes of death in 2,033 patients with non-transfusion-dependent Î²-thalassemia. Haematologica, 2021, 106, 2489-2492.	3.5	25
12	2021 update on clinical trials in Î²â€thalassemia. American Journal of Hematology, 2021, 96, 1518-1531.	4.1	38
13	Molecular Spectra and Frequency Patterns of Somatic Mutations in Arab Women with Breast Cancer. Oncologist, 2021, 26, e2086-e2089.	3.7	4
14	Relationship between transfusion burden, healthcare resource utilization, and complications in patients with betaâ€thalassemia in Taiwan: A realâ€world analysis. Transfusion, 2021, 61, 2906-2917.	1.6	12
15	A Phase 2a Study Evaluating the Safety and Pharmacokinetics (PK) of Luspatercept in Pediatric Patients with Transfusion-Dependent Î²-Thalassemia (TDT). Blood, 2021, 138, 4161-4161.	1.4	1
16	Iron deficiency anaemia revisited. Journal of Internal Medicine, 2020, 287, 153-170.	6.0	233
17	Less â€˜redsâ€™ more â€˜bluesâ€™: hemoglobin level and depression in non-transfusion-dependent thalassemia. Annals of Hematology, 2020, 99, 903-904.	1.8	9
18	Longâ€term improvement in cardiac magnetic resonance in Î²â€thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function. American Journal of Hematology, 2019, 94, 312-318.	4.1	13

#	Article	IF	Citations
19	Development of a thalassemiaâ€related thrombosis risk scoring system. American Journal of Hematology, 2019, 94, E207-E209.	4.1	7
20	Greater Red Blood Cell Transfusion Burden Is Associated with More Healthcare Resource Utilization in Patients with Beta-Thalassemia. Blood, 2019, 134, 5790-5790.	1.4	1
21	On the use of substandard medicines in hematology: An emerging concern in the Middle East and North Africa region. European Journal of Internal Medicine, 2018, 48, e40-e41.	2.2	2
22	Hypercoagulability and Vascular Disease. Hematology/Oncology Clinics of North America, 2018, 32, 237-245.	2.2	20
23	Emerging Therapies. Hematology/Oncology Clinics of North America, 2018, 32, 343-352.	2.2	5
24	Ineffective Erythropoiesis: Anemia and Iron Overload. Hematology/Oncology Clinics of North America, 2018, 32, 213-221.	2.2	54
25	Iron deficiency beyond erythropoiesis: should we be concerned?. Current Medical Research and Opinion, 2018, 34, 81-93.	1.9	83
26	Iron deficiency in chronic heart failure: caseâ€based practical guidance. ESC Heart Failure, 2018, 5, 764-771.	3.1	43
27	Iron overload across the spectrum of nonâ€transfusionâ€dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. British Journal of Haematology, 2017, 176, 288-299.	2.5	43
28	Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. American Journal of Hematology, 2017, 92, 1068-1078.	4.1	290
29	Serum ferritin values between 300 and 800 ng/mL in nontransfusionâ€dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. American Journal of Hematology, 2017, 92, E35-E37.	4.1	13
30	Oneâ€year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation. Pediatric Blood and Cancer, 2017, 64, 188-196.	1.5	24
31	Establishment of a bleeding score as a diagnostic tool for patients with rare bleeding disorders. Thrombosis Research, 2016, 148, 128-134.	1.7	22
32	Preoperative Pneumonia and Postoperative Venous Thrombosis: A Cohort Study of 427,656ÂPatients Undergoing Major General Surgery. World Journal of Surgery, 2016, 40, 1288-1294.	1.6	9
33	Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. European Journal of Internal Medicine, 2016, 28, 91-96.	2.2	14
34	Preoperative INR and postoperative major bleeding and mortality: A retrospective cohort study. Journal of Thrombosis and Thrombolysis, 2016, 41, 301-311.	2.1	22
35	Impact of Preoperative Anaemia and Blood Transfusion on Postoperative Outcomes in Gynaecological Surgery. PLoS ONE, 2015, 10, e0130861.	2.5	80
36	Sustained improvements in myocardial T2* over 2 years in severely ironâ€overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. American Journal of Hematology, 2015, 90, 91-96.	4.1	43

#	Article	IF	Citations
37	Hemoglobin level and morbidity in non-transfusion-dependent thalassemia. Blood Cells, Molecules, and Diseases, 2015, 55, 108-109.	1.4	20
38	A killer revealed: 10-year experience with beta-thalassemia intermedia. Hematology, 2014, 19, 196-198.	1.5	7
39	Association between cardiac T2* magnetic resonance imaging values and endocrine function tests in patients with Î²-thalassemia major. Blood Cells, Molecules, and Diseases, 2014, 52, 50-51.	1.4	1
40	Iron overload and chelation therapy in myelodysplastic syndromes. Critical Reviews in Oncology/Hematology, 2014, 91, 64-73.	4.4	46
41	Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo. Blood Cells, Molecules, and Diseases, 2014, 52, 88-90.	1.4	8
42	Prevalence and Risk Factors for Pulmonary Arterial Hypertension in a Large Group of Î²-Thalassemia Patients Using Right Heart Catheterization. Circulation, 2014, 129, 338-345.	1.6	101
43	Preventing Thalassemia in Lebanon: Successes and Challenges in a Developing Country. Hemoglobin, 2014, 38, 308-311.	0.8	13
44	Serum ferritin level and morbidity risk in transfusion-independent patients with Â-thalassemia intermedia: the ORIENT study. Haematologica, 2014, 99, e218-e221.	3.5	56
45	Postoperative outcomes following pancreaticoduodenectomy: how should age affect clinical practice?. World Journal of Surgical Oncology, 2013, 11, 131.	1.9	16
46	Treating iron overload in patients with nonâ€transfusionâ€dependent thalassemia. American Journal of Hematology, 2013, 88, 409-415.	4.1	67
47	Non-transfusion-dependent thalassemias. Haematologica, 2013, 98, 833-844.	3.5	231
48	End stage renal disease in six patients with beta-thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2013, 51, 146-148.	1.4	8
49	Deferiprone-induced seizures in a patient with Î²-thalassemia major. Blood Cells, Molecules, and Diseases, 2013, 51, 94-95.	1.4	3
50	Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with Î²-thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2013, 51, 35-38.	1.4	47
51	Cross-Talk between Available Guidelines for the Management of Patients with Beta-Thalassemia Major. Acta Haematologica, 2013, 130, 64-73.	1.4	49
52	Assessment and management of iron overload in Î²â€thalassaemia major patients during the 21st century: a realâ€life experience from the <scp>I</scp>talian <scp>W</scp>ebthal project. British Journal of Haematology, 2013, 161, 872-883.	2.5	31
53	The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura. Blood Reviews, 2013, 27, 71-76.	5.7	17
54	Smoking and the Risk of Mortality and Vascular and Respiratory Events in Patients Undergoing Major Surgery. JAMA Surgery, 2013, 148, 755.	4.3	140

#	Article	IF	Citations
55	Iron overload in Î²-thalassemia intermedia. Current Opinion in Hematology, 2013, 20, 187-192.	2.5	42
56	A liver mass in an iron-overloaded thalassaemia intermedia patient. British Journal of Haematology, 2013, 161, 1-1.	2.5	8
57	Iron overload in non-transfusion-dependent thalassemia. Thalassemia Reports, 2013, 3, 11.	0.5	2
58	Preoperative Hematocrit Concentration and the Risk of Stroke in Patients Undergoing Isolated Coronary-Artery Bypass Grafting. Anemia, 2013, 2013, 1-7.	1.7	7
59	Glomerular Hyperfiltration and Proteinuria in Transfusion-Independent Patients with Î²-Thalassemia Intermedia. Nephron, 2013, 121, c136-c143.	1.8	31
60	Clinical experience with fetal hemoglobin induction therapy in patients with Î²-thalassemia. Blood, 2013, 121, 2199-2212.	1.4	154
61	Postoperative Outcomes After Laparoscopic Splenectomy Compared With Open Splenectomy. Annals of Surgery, 2013, 257, 1116-1123.	4.2	29
62	Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with Â-thalassemia major. Haematologica, 2013, 98, 555-559.	3.5	12
63	Potential mechanisms for renal damage in beta-thalassemia. Journal of Nephrology, 2013, 26, 821-828.	2.0	22
64	Mechanisms of Renal Disease in Î²-Thalassemia. Journal of the American Society of Nephrology: JASN, 2012, 23, 1299-1302.	6.1	58
65	Â-Thalassemia Intermedia: A Clinical Perspective. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a013482-a013482.	6.2	102
66	Prevalence of Depression and Anxiety in Adult Patients with Î²-Thalassemia Major and Intermedia. International Journal of Psychiatry in Medicine, 2012, 44, 291-303.	1.8	24
67	The Spine in Î²-Thalassemia Syndromes. Spine, 2012, 37, 334-339.	2.0	27
68	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood, 2012, 120, 440-448.	1.4	107
69	A new chelator in the house. Blood, 2012, 119, 3191-3192.	1.4	1
70	Does absolute excess of alpha chains compromise the benefit of splenectomy in patients with thalassemia intermedia?. Haematologica, 2012, 97, 151-153.	3.5	5
71	Adverse operative outcomes in patients with anaemia â€“ Authors' reply. Lancet, The, 2012, 379, 1299-1300.	13.7	0
72	Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia. Blood Reviews, 2012, 26, S1-S2.	5.7	13

#	Article	IF	Citations
73	Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Reviews, 2012, 26, S16-S19.	5.7	105
74	Hypercoagulability in non-transfusion-dependent thalassemia. Blood Reviews, 2012, 26, S20-S23.	5.7	44
75	Contemporary approaches to treatment of beta-thalassemia intermedia. Blood Reviews, 2012, 26, S24-S27.	5.7	40
76	ADAMTSâ€13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2012, 10, 1556-1565.	3.8	74
77	Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura. Journal of Thrombosis and Thrombolysis, 2012, 34, 416-418.	2.1	2
78	Mondorâ€™s Disease of the Breast in the Context of Inherited Thrombophilia. Breast Journal, 2012, 18, 373-374.	1.0	2
79	The effect of maternal fasting during Ramadan on preterm delivery: a prospective cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 1379-1386.	2.3	40
80	Switching patients from warfarin to dabigatran therapy: To RE-LY or not to rely. International Journal of Cardiology, 2012, 154, e27-e28.	1.7	2
81	Carbamazepine-induced thrombocytopenia. Blood Cells, Molecules, and Diseases, 2012, 48, 197-198.	1.4	8
82	Left ventricular noncompaction in patients with Î²â€thalassemia: Uncovering a previously unrecognized abnormality. American Journal of Hematology, 2012, 87, 1079-1083.	4.1	23
83	Hypercoagulability in Î²-thalassemia: a status quo. Expert Review of Hematology, 2012, 5, 505-512.	2.2	70
84	Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with Î²-thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2012, 49, 136-139.	1.4	42
85	Cerebral infarction in Î²-thalassemia intermedia: Breaking the silence. Thrombosis Research, 2012, 130, 695-702.	1.7	81
86	Fetal hemoglobin levels and morbidity in untransfused patients with Î²-thalassemia intermedia. Blood, 2012, 119, 364-367.	1.4	85
87	Correlation of non-mass-like abnormal MR signal intensity with pathological findings surrounding pediatric osteosarcoma and Ewingâ€™s sarcoma. Skeletal Radiology, 2012, 41, 1453-1461.	2.0	16
88	Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial Cancer. Journal of Cancer, 2012, 3, 362-368.	2.5	3
89	Serum ferritin levels and endocrinopathy in medically treated patients with Î² thalassemia major. Annals of Hematology, 2012, 91, 1107-1114.	1.8	79
90	von Willebrand factor propeptide to antigen ratio in acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2012, 10, 728-730.	3.8	6

#	Article	IF	Citations
91	Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. Journal of Thrombosis and Haemostasis, 2012, 10, 615-621.	3.8	362
92	Elevated prepartum fibrinogen levels are not associated with a reduced risk of postpartum hemorrhage. Journal of Thrombosis and Haemostasis, 2012, 10, 1451-1453.	3.8	24
93	Brain positron emission tomography in splenectomized adults with Î²-thalassemia intermedia: uncovering yet another covert abnormality. Annals of Hematology, 2012, 91, 235-241.	1.8	27
94	Serum Ferritin Levels and Morbidity in Î²-Thalassemia Intermedia: A 10-Year Cohort Study. Blood, 2012, 120, 1021-1021.	1.4	11
95	Evaluation of the 5 Mg/g Liver Iron Concentration Threshold and Its Association with Vascular and Endocrine/Bone Morbidity in Î²-Thalassemia Intermedia. Blood, 2012, 120, 1024-1024.	1.4	1
96	Elevated Hematocrit Concentration and the Risk of Mortality and Vascular Events in Patients Undergoing Major Surgery.. Blood, 2012, 120, 2088-2088.	1.4	2
97	Prevalence and Risk Factors of Left Ventricular Noncompaction in Patients with Î²-Thalassemia.. Blood, 2012, 120, 2127-2127.	1.4	4
98	Iron Chelation Therapy and Mobilization of Hematopoietic Peripheral Progenitors in Patients with Î²-Thalassemia Major. Blood, 2012, 120, 5178-5178.	1.4	0
99	Assessment and Management of Iron Overload in Î²-Thalassemia Major Patients in Italy: A Real-Life Experience From the WebthalÂ® Project. Blood, 2012, 120, 1030-1030.	1.4	0
100	Estimation of the Prevalence of Pulmonary Artery Hypertension in a Large Group of Î²-Thalassemia Patients Using Right Heart Catheterization. Blood, 2012, 120, 3262-3262.	1.4	0
101	Predicting venous thromboembolism in hospitalized medical patients: are we there yet?. Expert Review of Hematology, 2011, 4, 1-3.	2.2	3
102	THALASSEMIA AND VENOUS THROMBOEMBOLISM. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011025.	1.3	39
103	Thrombosis in Thalassemia: Why are we so Concerned?. Hemoglobin, 2011, 35, 503-510.	0.8	40
104	Pulmonary Complications of Sickle Cell Disease. Hemoglobin, 2011, 35, 625-635.	0.8	7
105	Bone disease and skeletal complications in patients with Î² thalassemia major. Bone, 2011, 48, 425-432.	2.9	127
106	Risk factors for pulmonary hypertension in patients with Î² thalassemia intermedia. European Journal of Internal Medicine, 2011, 22, 607-610.	2.2	56
107	Antibiotic use and risk of gynecological cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 159, 388-393.	1.1	12
108	Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with Î² thalassemia intermedia. Blood Cells, Molecules, and Diseases, 2011, 47, 232-234.	1.4	55

#	Article	IF	Citations
109	Implementation of an Emergency Department Computer System: Design Features That Users Value. Journal of Emergency Medicine, 2011, 41, 693-700.	0.7	32
110	Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet, The, 2011, 378, 1396-1407.	13.7	1,007
111	Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood, 2011, 118, 894-898.	1.4	62
112	Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major. Haematologica, 2011, 96, e5-e6.	3.5	6
113	Optimal management of Î² thalassaemia intermedia. British Journal of Haematology, 2011, 152, 512-523.	2.5	187
114	Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. European Journal of Haematology, 2011, 87, 73-79.	2.2	39
115	Brain magnetic resonance angiography in splenectomized adults with Î²-thalassemia intermedia. European Journal of Haematology, 2011, 87, 539-546.	2.2	46
116	Iron in sickleâ€cell disease: What have we learned over the years?. Pediatric Blood and Cancer, 2011, 56, 182-190.	1.5	18
117	Is VEGF a predictive biomarker to anti-angiogenic therapy?. Critical Reviews in Oncology/Hematology, 2011, 79, 103-111.	4.4	31
118	Managing unresponsiveness or intolerance to deferasirox therapy: a tale of two doses. Expert Review of Hematology, 2011, 4, 411-414.	2.2	2
119	Elevated liver iron concentration is a marker of increased morbidity in patients with Â thalassemia intermedia. Haematologica, 2011, 96, 1605-1612.	3.5	153
120	ANTITHROMBOTIC PROPHYLAXIS IN THE MIDDLE EAST. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011023.	1.3	2
121	Iron Chelation Therapy for Transfusional Iron Overload: A Swift Evolution. Hemoglobin, 2011, 35, 565-573.	0.8	10
122	Cerebral Infarction in Children with Sickle Cell Disease: A Concise Overview. Hemoglobin, 2011, 35, 618-624.	0.8	7
123	1-Year Results From A Prospective Randomized Trial Comparing Phlebotomy with Deferasirox for the Treatment of Iron Overload in Pediatric Patients with Thalassemia Major Following Curative Stem Cell Transplantation. Blood, 2011, 118, 904-904.	1.4	2
124	Coagulation Factor Activity Level and Clinical Bleeding Severity in Rare Bleeding Disorders: Results From the European Network of Rare Bleeding Disorders (EN-RBD),. Blood, 2011, 118, 3312-3312.	1.4	0
125	The role of liver iron in hepatitis C antiviral treatment. European Journal of Gastroenterology and Hepatology, 2010, 22, 769.	1.6	1
126	Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease. Blood, 2010, 115, 2980-2981.	1.4	27

#	Article	IF	Citations
127	Covert brain ischaemia in splenectomised adults with thalassemia intermedia: An emerging entity. Thrombosis and Haemostasis, 2010, 104, 652-653.	3.4	4
128	Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Annals of Hematology, 2010, 89, 585-589.	1.8	55
129	Thrombotic renal and adrenal manifestations of primary antiphospholipid syndrome. Rheumatology International, 2010, 30, 993-994.	3.0	0
130	Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Indian Journal of Surgical Oncology, 2010, 1, 68-75.	0.7	3
131	Primary colorectal lymphoma. Medical Oncology, 2010, 27, 249-254.	2.5	18
132	Malignancy and hypercoagulability: a two-way association revisited. Journal of Thrombosis and Thrombolysis, 2010, 30, 340-341.	2.1	2
133	The wanderer. American Journal of Obstetrics and Gynecology, 2010, 202, 662.e1.	1.3	1
134	Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusionâ€independent thalassemia intermedia compared to regularly transfused thalassemia major patients. American Journal of Hematology, 2010, 85, 288-290.	4.1	61
135	Iron chelation therapy for patients with sickle cell disease and iron overload. American Journal of Hematology, 2010, 85, 782-786.	4.1	15
136	Renal complications in transfusion-dependent beta thalassaemia. Blood Reviews, 2010, 24, 239-244.	5.7	70
137	Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. Journal of Thrombosis and Haemostasis, 2010, 8, 54-59.	3.8	72
138	Splenectomy and thrombosis: the case of thalassemia intermedia. Journal of Thrombosis and Haemostasis, 2010, 8, 2152-2158.	3.8	120
139	Ageâ€related complications in treatmentâ€naÃ¯ve patients with thalassaemia intermedia. British Journal of Haematology, 2010, 150, 486-489.	2.5	100
140	Redefining thalassemia as a hypercoagulable state. Annals of the New York Academy of Sciences, 2010, 1202, 231-236.	3.8	78
141	JAK2V617F and Prothrombin G20210A Gene Mutations in a Patient With Budd-Chiari Syndrome and Essential Thrombocythemia. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 472-474.	1.7	2
142	Use of Recombinant Activated Factor VII for Intractable Bleeding in Patients Without Hemophilia: A Developing Country Tertiary Care Centerâ€™s Experience. Clinical and Applied Thrombosis/Hemostasis, 2010, 16, 658-662.	1.7	0
143	Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood, 2010, 115, 1886-1892.	1.4	315
144	The impact of zoledronic acid on regenerate and native bone after consolidation and removal of the external fixator: An animal model study. Bone, 2010, 46, 363-368.	2.9	10

#	Article	IF	Citations
145	A closer look at paroxysmal nocturnal hemoglobinuria. European Journal of Internal Medicine, 2010, 21, 260-267.	2.2	23
146	A computed tomography Iron Index. European Journal of Radiology, 2010, 75, 189-190.	2.6	0
147	Iron Overload Indices In Thalassemia Major Children Cured by Stem Cell Transplantation at Enrollment In a Prospective Randomized Trial Comparing Phlebotomy and Deferasirox. Blood, 2010, 116, 2082-2082.	1.4	1
148	Risk Factors for Pulmonary Hypertension In Patients with Thalassemia Intermedia. Blood, 2010, 116, 2069-2069.	1.4	0
149	Prevalence of Anxiety and Depression In Transfusion-Independent Thalassemia Intermedia Compared to Regularly-Transfused Patients with Thalassemia Major. Blood, 2010, 116, 5167-5167.	1.4	0
150	The risk of local recurrence along the core-needle biopsy tract in patients with bone sarcomas. Iowa orthopaedic journal, The, 2010, 30, 80-3.	0.5	29
151	Solitary Hydatid Cyst of the Thigh: A Challenging Diagnosis. Vector-Borne and Zoonotic Diseases, 2009, 9, 743-745.	1.5	5
152	Sickle Cell Disease at the Dawn of the Molecular Era. Hemoglobin, 2009, 33, S93-S106.	0.8	9
153	Axillary Lymph Node Ratio Revisited. Journal of Clinical Oncology, 2009, 27, e67-e67.	1.6	1
154	Aspirin Resistance. Advances in Hematology, 2009, 2009, 1-10.	1.0	32
155	Antiphospholipid Syndrome, Microalbuminuria, and Risk of Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2009, 302, 945.	7.4	1
156	Childhood stroke in a child with familial Mediterranean fever carrying several prothrombotic risk factors. Lupus, 2009, 18, 845-847.	1.6	23
157	Caught up with Time. Digestive Surgery, 2009, 26, 24-24.	1.2	0
158	Re: Anti-Angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of the National Cancer Institute, 2009, 101, 1657-1657.	6.3	0
159	High-output cardiac failure secondary to a large arteriovenous fistula: a persistent threat to the dialysis and kidney transplant patient. CKJ: Clinical Kidney Journal, 2009, 2, 147-148.	2.9	5
160	Small bowel intussusception following blunt abdominal trauma in an adult patient. Emergency Medicine Journal, 2009, 26, 752-753.	1.0	5
161	Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. European Journal of Haematology, 2009, 83, 565-571.	2.2	33
162	Clinical images: Severe photosensitive skin reaction secondary to an herbal treatment in a patient with systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 60, 2854-2854.	6.7	1

#	Article	IF	Citations
163	The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon. Rheumatology International, 2009, 29, 1255-1257.	3.0	1
164	Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration?. Annals of Hematology, 2009, 88, 1033-1034.	1.8	9
165	Transfusion independence in Diamond-Blackfan anemia after deferasirox therapy. Annals of Hematology, 2009, 88, 1263-1264.	1.8	8
166	Levels of nonâ€transferrinâ€bound iron as an index of iron overload in patients with thalassaemia intermedia. British Journal of Haematology, 2009, 146, 569-572.	2.5	66
167	Pregnancy and risk of venous thromboembolism in developing countries. British Journal of Haematology, 2009, 146, 691-692.	2.5	0
168	Ratio Between Positive Lymph Nodes and Total Excised Axillary Lymph Nodes as an Independent Prognostic Factor for Overall Survival in Patients with Nonmetastatic Lymph Node-Positive Breast Cancer. Annals of Surgical Oncology, 2009, 16, 3388-3395.	1.5	41
169	Effects of divalproex sodium on hemoglobin level. Blood Cells, Molecules, and Diseases, 2009, 43, 49-52.	1.4	3
170	Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thrombosis Research, 2009, 123, 679-686.	1.7	53
171	Distinctive Presentation of a Diaphragmatic Hernia 15 Years After A Traumatic Insult. Annals of Thoracic Surgery, 2009, 88, 651-653.	1.3	4
172	Thalassaemia Intermedia: an Update. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009004.	1.3	34
173	Iron Overload: Consequences, Assessment, and Monitoring. Hemoglobin, 2009, 33, S46-S57.	0.8	59
174	Insight onto the Pathophysiology and Clinical Complications of Thalassemia Intermedia. Hemoglobin, 2009, 33, S145-S159.	0.8	33
175	Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone. Hemoglobin, 2009, 33, S58-S69.	0.8	33
176	The Hypercoagulable State in Thalassemia Intermedia. Hemoglobin, 2009, 33, S160-S169.	0.8	16
177	Recombinant Activated Factor VII in Abdominal Aortic Emergencies. Annals of Surgery, 2009, 249, 692.	4.2	0
178	Thromboangiitis obliterans and the inherited thrombophilias: does an association merit consideration?. Blood Coagulation and Fibrinolysis, 2009, 20, 223-224.	1.0	1
179	Silent Brain Abnormalities in Thalassemia Intermedia: A Combined MRI/PET Study.. Blood, 2009, 114, 4077-4077.	1.4	8
180	A novel genotype c.1228C>G/c.1448C-1498C (L371V/Rec-NciI) in a 3-year-old child with type 1 Gaucher disease. Journal of Applied Genetics, 2008, 49, 421-424.	1.9	1

#	ARTICLE	IF	CITATIONS
181	Iron and hepatitis C: What can we learn from thalassemia major?. Liver International, 2008, 28, 892-893.	3.9	2
182	Abdominal Manifestations of Multiple Myeloma: A Retrospective Radiologic Overview. Clinical Lymphoma and Myeloma, 2008, 8, 348-351.	1.4	24
183	Challenges Associated With Prolonged Survival of Patients With Thalassemia: Transitioning From Childhood to Adulthood. Pediatrics, 2008, 121, e1426-e1429.	2.1	34
184	Burkitt's lymphoma of the colon and bronchi: three case reports. Cases Journal, 2008, 1, 15.	0.4	6
185	Solitary mediastinal lymph node metastasis in rectosigmoid carcinoma: a case report. Cases Journal, 2008, 1, 69.	0.4	15